Metformin as secondary therapy in a defined population with type 2 diabetes

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1678-1687

  Brown, Jonathan B ^a   Pedula, Kathryn L ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Health maintenance organization; Hyperglycemia; Metformin; Registries; Sulfonylurea failure; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; DRUG EFFICACY; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REGISTER; TREATMENT FAILURE;

EID: 0032740178     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80047-2     Document Type: Article

References (24)

1. 1. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15:755-772.
2. 2. Cusi K, DeFronzo RA, Consoli A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:4059-4067.
3. 3. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157:1802-1817.
4. 4. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102:99-110.
5. 5. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
6. 6. Guthrie R. Treatment of non-insulin-dependent diabetes mellitus with metformin. J Am Board Fam Pract. 1997;10:213-221.
7. 7. Santos RF, Nomizo R, Wajhenberg BL, et al. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes. Diabetes Metabol. 1995;21:274-280.
8. 8. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
9. 9. Grant PJ. The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996;19:64-66.
10. 10. Gregario F, Fillipponi P, Santucci A, et al. Metformin, plasma glucose and free fatty acids in type II diabetic outpatients: Results of a clinical study. Diabetes Res Clin Pract. 1997;37:21-33.
11. 11. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-II Study. Am J Med. 1997;103:483-490.
12. 12. Bailey CJ, Nattrass M. Treatment - metformin. Bailliere's Clin Endocrinol Metab. 1988;2:455-476.
13. 13. Gan SC, Barr J, Arieff AL, Pearl RG. Biguanide-associated lactic acidosis: Case report and review of the literature. Arch Intern Med. 1992;152:2333-2336.
14. 14. Greenlick M, Freeborn D, Pope C. Health Care Research in an HMO: Two Decades of Discovery. Baltimore, Md: The Johns Hopkins University Press; 1998.
15. 15. Ford ES, Malarcher AM, Herman WH, Aubert RE. Diabetes mellitus and cigarette smoking. Findings from the 1989 National Health Interview Survey. Diabetes Care. 1994;17:688-692.
16. 16. US Department of Health & Human Services. National Center for Health Statistics: Third National Health and Nutrition Examination Survey, 1988-1994 [on CD-ROM]. Washington, DC: Department of Health and Human Services; 1996. Catalog 76200.
17. 17. Gerich JE. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231-1245.
18. 18. Stenman S, Meleander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 1993;118:169-172.
19. 19. Rosner B. Fundamentals of Biostatistics. Boston: PWS Publishers; 1986:115-116.
20. 20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
21. 21. UKPDS Group. UKPDS 33: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-851.
22. 22. Klein R, Klein BEK, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996;124:90-96.
23. 23. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
24. 24. Clark CM Jr. The National Diabetes Education Program: Changing the way diabetes is treated. Ann Intern Med. 1999; 130:324-326.